- cafead Nov 17, 2022 at 10:43: AM
via It turns out that GSK’s broad retreat from cell therapies went even deeper than it let on.
As Immatics, which scored $50 million upfront from GSK back in 2020 to collaborate on two T cell receptor therapies for solid tumors, revealed in its Q3 update:
On October 24, 2022, GSK provided Immatics with notice of its decision to terminate their collaboration.
article source
As Immatics, which scored $50 million upfront from GSK back in 2020 to collaborate on two T cell receptor therapies for solid tumors, revealed in its Q3 update:
On October 24, 2022, GSK provided Immatics with notice of its decision to terminate their collaboration.
article source